A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy
Status:
Active, not recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
The XEN1101 Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study
that will evaluate the clinical efficacy, safety and tolerability of increasing doses of
XEN1101 administered as adjunctive treatment in adult patients diagnosed with focal epilepsy,
followed by an optional open-label extension (OLE).